SCHEMBL4966622

SCHEMBL4966622

CC(=O)c1cccc(C(=O)[O-])c1O.CC(=O)c1cccc(C(=O)[O-])c1O.CC(=O)c1cccc(C(=O)[O-])c1O.[Al+3]

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.47
ALDH1A1 P00352 4/20 0.47
HPGD P15428 3/20 0.47
MAPT P10636 2/20 0.40
THRB P10828 1/20 0.40
MEN1 O00255 1/20 0.40
NSD2 O96028 1/20 0.40
POLB P06746 1/20 0.40
KMT2A Q03164 1/20 0.40
MCL1 Q07820 1/20 0.40
HSD17B10 Q99714 1/20 0.39
SMN1; SMN2 Q16637 3/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
BRPF1 P55201 1/20 0.37
PBRM1 Q86U86 1/20 0.36
ALB P02768 1/20 0.35
MMP2 P08253 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2133320 0.96 KDM4E (0.52) KDM4EALDH1A1HPGDMAPTTHRB
SCHEMBL4393614 0.96 KDM4E (0.47) KDM4EALDH1A1HPGDMAPTTHRB
SCHEMBL20484784 0.96 KDM4E (0.47) KDM4EALDH1A1HPGDMAPTTHRB
Silver SCHEMBL191053 0.96 KDM4E (0.47) KDM4EALDH1A1HPGDMAPTTHRB
SCHEMBL26227 0.96 KDM4E (0.47) KDM4EALDH1A1HPGDMAPTTHRB
Lithium Ion SCHEMBL1457619 0.96 KDM4E (0.47) KDM4EALDH1A1HPGDMAPTTHRB
SCHEMBL10404578 0.96 KDM4E (0.47) KDM4EALDH1A1HPGDMAPTTHRB
Potassium Ion SCHEMBL5250865 0.96 KDM4E (0.47) KDM4EALDH1A1HPGDMAPTTHRB
SCHEMBL25283 0.96 KDM4E (0.47) KDM4EALDH1A1HPGDMAPTTHRB
SCHEMBL11433030 0.96 KDM4E (0.47) KDM4EALDH1A1HPGDMAPTTHRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 132 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115404039-B Polyurethane adhesive and preparation method and application thereof 杭州之江有机硅化工有限公司 2023-06-16 CN claimed
CN-115404039-A Polyurethane adhesive and preparation method and application thereof 杭州之江有机硅化工有限公司 2022-11-29 CN claimed
CN-1294519-A Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient INPHARMA SA (CH) 2001-05-09 CN claimed
US-5128334-A Side effect reduction, ascorbic acid or derivative IMMUNO JAPAN INC. (JP) 1992-07-07 US claimed
EP-0437083-A1 Analgesic and anti-inflammatory medicine IMMUNO JAPAN INC. (JP) 1991-07-17 EP claimed
US-4229446-A ANALGESICS, ANTIPYRETICS, ANTIINFLAMMATORY AGENTS KYOWA HAKKO KOGYO CO., LTD. (JP) 1980-10-21 US claimed
JP-56077223-A None JP disclosed
JP-56073020-A None JP disclosed
JP-56115719-A None JP disclosed
US-12622949-B2 Compositions containing rapid-acting insulin analogues CASE WESTERN RESERVE UNIVERSITY (US) 2026-05-12 US disclosed
US-20250099551-A1 THERMOSTABLE FORMULATION OF A21G HUMAN INSULIN ADOCIA (FR) 2025-03-27 US disclosed
EP-3720471-B1 COMPOSITIONS IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION COMPRISING HUMAN GLUCAGON AND A COPOLYAMINO ACID ADOCIA (FR) 2023-11-29 EP disclosed
EP-4019039-B1 COMPOSITIONS IN THE FORM OF AN AQUEOUS INJECTABLE SOLUTION COMPRISING AT LEAST ONE HUMAN INSULIN A21G AND A GLUCAGON SUPPRESSOR WITH PRANDIAL ACTION ADOCIA (FR) 2023-10-11 EP disclosed
JP-S5677223-A ACETYLSALICYLIC ACID TABLET LION CORP 1981-06-25 JP disclosed
JP-S5673020-A TABLET OF ALUMINUM ACETYLSALICYLATE LION CORP 1981-06-17 JP disclosed
EP-0019000-A1 OSTEOPLASTIC PROMOTOR TEIJIN LIMITED (JP) 1980-11-26 EP disclosed
US-4229446-A ANALGESICS, ANTIPYRETICS, ANTIINFLAMMATORY AGENTS KYOWA HAKKO KOGYO CO., LTD. (JP) 1980-10-21 US disclosed
US-4229446-A ANALGESICS, ANTIPYRETICS, ANTIINFLAMMATORY AGENTS KYOWA HAKKO KOGYO CO., LTD. (JP) 1980-10-21 US disclosed
US-4229446-A ANALGESICS, ANTIPYRETICS, ANTIINFLAMMATORY AGENTS KYOWA HAKKO KOGYO CO., LTD. (JP) 1980-10-21 US disclosed
US-4019872-A Producing sodium carbonate monohydrate from carbonate solution including addition of aluminum ions INTERMOUNTAIN RESEARCH AND DEVELOPMENT CORPORATION (US) 1977-04-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12622949-B2 Compositions containing rapid-acting insulin analogues IAPP, HBB, GLP1R KDM4E 4417/4885ALDH1A1 4789/4885HPGD 4472/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.